A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1193-1202

  Le Cesne, Axel ^a   Yovine, Alejandro ^b   Blay, Jean Yves ^c   Delaloge, Suzette ^a   Maki, Robert G ^d   Misset, Jean Louis ^b   Frontelo, Pilar ^e   Nieto, Antonio ^e   Jiao, Juhui James ^f   Demetri, George D ^g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE LÉON BÉRARD   (France)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e PHARMAMAR S A   (Spain)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; ET 743; Phase II; Safety; Singleagent; Trabectedin; Yondelis

Indexed keywords

TRABECTEDIN;

ADOLESCENT; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALOPECIA; ARTICLE; BLEEDING DISORDER; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; EWING SARCOMA; EXTRAVASATION; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL STROMAL TUMOR; HEART DISEASE; HUMAN; INFECTION; KIDNEY CANCER; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SCHOOL CHILD; SENSORY NEUROPATHY; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; DIOXOLES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RHABDOMYOLYSIS; TETRAHYDROISOQUINOLINES; YOUNG ADULT;

EID: 84864348875     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9662-0     Document Type: Article

References (39)

1. Carter NJ, Keam SJ (2007) Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67 (15):2257-2276 (Pubitemid 47557097)
2. Zewail-Foote M, Hurley LH (1999) Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 42(14):2493-2497 (Pubitemid 29344290)
3. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S (2006) Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action ofantitumortrabectedin. Cancer Res 66(16):8155-8162 (Pubitemid 44299183)
4. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW (2002) Ecteinascidin-743 inhibits activated but not constitutive transcrip-tion. Cancer Res 62(12):3377-3381 (Pubitemid 34651382)
5. Guirouilh-Barbat J, Redon C, Pommier Y (2008) Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 19(9):3969-3981
6. Martinez EJ, Corey EJ, Owa T (2001) Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 8(12):1151-1160 (Pubitemid 34029884)
7. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT (1999) High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10(10):1233-1240 (Pubitemid 29533575)
8. Izbicka E, Lawrence R, Raymond E et al (1998) In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9(9):981-987 (Pubitemid 28496707)
9. Le Cesne A, von Mehren M, Chawla S et al (2007) Assessing the clinical impact of trabectedin in patients with leiomyosar-comas or liposarcomas (L-sarcomas) progressing despite prior conventional chemotherapy: clinical benefit rate, growth mod-ulation index and tumor variation as parameters of treatment effect in a randomised international trial of two trabectedin dosing regimens. Eur J Cancer 5(4 (Supplement)):405 (abstract 7512)
10. Monk BJ, Herzog T, Kaye S et al (2008) A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann Oncol 19(Supplement 8):viii1-viii4. doi:10.1093/annonc/mdn649, LBA4
11. Monk BJ, Herzog TJ, Kaye S, et al (in press) Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol
12. Zelek L, Yovine A, Brain E et al (2006) A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 94 (11):1610-1614 (Pubitemid 43924922)
13. Paz-Ares L, Rivera-Herreros F, Diaz-Rubio E et al (2007) Phase II study of trabectedin in pretreated patients with advanced colorec-tal cancer. Clin Colorectal Cancer 6(7):522-528 (Pubitemid 46918158)
14. Yovine A, Riofrio M, Blay JY et al (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22(5):890-899 (Pubitemid 41103601)
15. Sessa C, De Braud F, Perotti A et al (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23(9):1867-1874 (Pubitemid 46211364)
16. Ryan DP, Puchalski T, Supko JG et al (2002) A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 7(6):531-538 (Pubitemid 36009001)
17. Krasner CN, McMeekin DS, Chan S et al (2007) A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97(12):1618-1624 (Pubitemid 350249358)
18. Garcia-Carbonero R, Supko JG, Manola J et al (2004) Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22(8):1480-1490 (Pubitemid 41103631)
19. Garcia-Carbonero R, Supko JG, Maki RG et al (2005) Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharma-cokinetic study. J Clin Oncol 23(24):5484-5492
20. Demetri GD, Chawla SP, von Mehren M et al (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracy-clines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27(25):4188-4196
21. Del Campo JM, Roszak A, Bidzinski M et al (2009) Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 hor 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 20(11):1794-1802
22. Laverdiere C, Kolb EA, Supko JG et al (2003) Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98(4):832-840 (Pubitemid 36959281)
23. McMeekin DS, Lisyanskaya A, Crispens M et al (2009) Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. Gynecol Oncol 114(2):288-292
24. European Medicines Agency (EMEA). Trabectedin 2007. Avail-able from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/yondelis/H-773-en6.pdf AccessedApril 2010
25. Gomez J, Lopez Lazaro L, Guzman C, Gonzalez A, Misset JL, Twelves C et al (2000) Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol 19:187 (abstract 727)
26. Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P (2008) Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yonde-lis) induced neutropenia. Clin Pharmacol Ther 83(1):130-143
27. van Oosterom AT, Mouridsen HT, Nielsen OS et al (2002) Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38(18):2397-2406 (Pubitemid 35387492)
28. Frustaci S, Foladore S, Buonadonna A et al (1993) Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann Oncol 4(8):669-672 (Pubitemid 23291813)
29. Palumbo R, Neumaier C, Cosso M et al (1999) Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer 35(1):66-72 (Pubitemid 29079493)
30. Reichardt P, Tilgner J, Hohenberger P, Dorken B (1998) Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 16(4):1438-1443 (Pubitemid 28175763)
31. Spira AI, Ettinger DS (2002) The use of chemotherapy in soft-tissue sarcomas. Oncologist 7(4):348-359 (Pubitemid 34919959)
32. Beumer JH, Schellens JH, Beijnen JH (2005) Hepatotoxicity and metabolism oftrabectedin: a literature review. Pharmacol Res 51 (5):391-398 (Pubitemid 40321008)
33. Salazar R, Pardo B, Majem M et al (2006) Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3 h/q3w) in patients with advanced cancer and hepatic function disorder. J Clin Oncol 24(18-suppl):2080- (Meeting Abstracts)
34. Taamma A, Misset JL, Riofrio M et al (2001) Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19(5):1256-1265 (Pubitemid 32202528)
35. Puchalski TA, Ryan DP, Garcia-Carbonero R et al (2002) Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50(4):309-319
36. Yver A, Cohen R, Williams D, Von Mehren M (2006) Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD). J Clin Oncol. ASCO Annual Meeting Proceedings Part I, Vol 24(No. 18S, June 20 Supplement): 9568
37. Fetterly GJ, Owen JS, Stuyckens K et al (2008) Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabecte-din (ET-743) treatment. Cancer Chemother Pharmacol 62(1):135-147 (Pubitemid 351537854)
38. Chuk MK, Balis FM, Fox E (2009) Trabectedin. Oncologist 14 (8):794-799
39. Lee JK, Leslie EM, Zamek-Gliszczynski MJ, Brouwer KL (2008) Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity Toxicol Appl Pharmacol 228(1):17-23